at Zacks.com (Jan 15, 2015)
Shares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting new 52-week lows after the drug-maker withdrew its Investigational New Drug application for its antiviral nucleoside treatment for hepatitis C, BCX5191. The FDA has raised concerns related to the drug's preclinical toxicity profile at levels necessary for it to be effective.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at MarketWatch.com (Jan 14, 2015)
at Zacks.com (Jan 14, 2015)
at Benzinga.com (Jan 14, 2015)
at CNBC.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs